Whoop has raised $575m, bringing the self-ascribed human performance company to a valuation of over $10bn, and adding a medtech giant to its investor pool.
Whoop’s Series G financing round was led by Collaborative Fund and included participation from a broad-ranging investor set, including the Qatar Investment Authority (QIA), Mayo Clinic and Abbott. Individual investors, including former football ace Cristiano Ronaldo and NBA star LeBron James also participated.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Joining as a strategic investor, Whoop said that with Abbott’s broad portfolio spanning diagnostics, medical devices, nutrition, and generic medicines, the medtech giant would bring “deep healthcare expertise, scale, and a track record of health tech innovation”, noting that the companies share a commitment to “empowering people to take control of their health”.
Powered by 24 billion hours of physiological data and purpose-built artificial intelligence (AI) models, Whoop is a wearable that is designed to deliver predictive, personalised health insights around a plethora of metrics, including the provision of insight into how factors such as sleep, nutrition, and stress are impacting users’ overall performance and long-term health.
With the latest financing in hand, Whoop plans to accelerate its global expansion and scale its platform.
Whoop CEO Will Ahmed said: “Our raise brings together the world’s most sophisticated investors, leading health institutions, and iconic global athletes behind the mission to unlock human performance and health span.
“We are building the personal health platform that people use to improve their health and livelihood.”
The blurred line between wearables and medical devices
Whoop markets its product as a wearable and its healthcare insights platform as an app, rather than designating these facets of its offering as a medical device. In July 2025, however, the US Food and Drug Administration (FDA) issued the company a warning letter. The agency asserted that by marketing its wearable with a blood pressure insights (BPI) feature in the US without marketing clearance or approval, Whoop was “in violation” of the Federal Food, Drug, and Cosmetic Act (FD&C).
The FDA’s letter explained: “This conclusion is bolstered by both your firm’s statements about BPI … e.g., ‘Higher blood pressure may be an indicator of poor sleep’ and BPI’s design, which outputs a blood pressure measurement to users and provides the reading on a gauge that uses green, yellow, and orange color-coding to indicate a target blood pressure range.”
With these factors in mind, the FDA concluded that Whoop met the threshold of a medical device and should have sought regulatory clearance, likely through the FDA’s 510(k) equivalency pathway.
Whoop publicly rejected the FDA’s claims, with Ahmed writing in a LinkedIn post that the company did not plan on removing the feature from its app and that it “remained confident” that the law was on its side.
“Our argument is clear: Blood Pressure Insights is a wellness feature, informing our members about the impact of blood pressure on sleep, recovery, and performance. It does not diagnose any condition. It’s clearly labelled as not for medical use. It even goes so far as to require members to proactively acknowledge that they understand it’s not a medical device,” Ahmed’s post continued.
Legal observers advised companies marketing wellness products to consult with the FDA at an early stage to clarify whether its product would be subject to regulatory enforcement or fall below this threshold.
Blythe Karow, founder of medtech consultancy The Karow Advisory Group, expressed her view that the FDA’s legal theory was “always a bit of a stretch”.
“If any biometric that can be used for diagnosis automatically becomes a medical device, then the wellness device exemption congress created in the 21st Century Cures Act — that software intended for general wellness and not medical diagnosis or treatment is not considered a medical device — becomes meaningless,” Karow noted.
